Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anderton, M. J.
Right arrow Articles by Williams, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anderton, M. J.
Right arrow Articles by Williams, M. L.
Clinical Cancer Research Vol. 10, 5233-5241, August 1, 2004
© 2004 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Pharmacokinetics and Tissue Disposition of Indole-3-carbinol and Its Acid Condensation Products after Oral Administration to Mice

Mark J. Anderton1, Margaret M. Manson1, Richard D. Verschoyle1, Andreas Gescher1, John H. Lamb1, Peter B. Farmer1, William P. Steward1 and Marion L. Williams2

1 Cancer Biomarkers and Prevention Group, Departments of Biochemistry and Cancer Studies and Molecular Medicine, University of Leicester, Leicester, United Kingdom, and 2 National Institute on Aging, Gerontology Research Center, Baltimore, Maryland

Indole-3-carbinol (I3C) and 3,3'-diindolylmethane (DIM) are promising cancer chemopreventive agents in rodent models, but there is a paucity of data on their pharmacokinetics and tissue disposition. The disposition of I3C and its acid condensation products, DIM, [2-(indol-3-ylmethyl)-indol-3-yl]indol-3-ylmethane (LTr1), indolo[3,2b]carbazole (ICZ) and 1-(3-hydroxymethyl)-indolyl-3-indolylmethane (HI-IM) was studied, after oral administration of I3C (250 mg/kg) to female CD-1 mice. Blood, liver, kidney, lung, heart, and brain were collected between 0.25 and 24 h after administration and the plasma and tissue concentrations of I3C and its derivatives determined by high-performance liquid chromotography. I3C was rapidly absorbed, distributed, and eliminated from plasma and tissues, falling below the limit of detection by 1 h. Highest concentrations of I3C were detected in the liver where levels were approximately 6-fold higher than those in the plasma. Levels of DIM, LTr1, and HI-IM were much lower, although they persisted in plasma and tissues for considerably longer. DIM and HI-IM were still present in the liver 24 h after I3C administration. Tissue levels of DIM and LTr1 were found to be in equilibrium with plasma at almost every time point measured. In addition to acid condensation products of I3C, a major oxidative metabolite (indole-3-carboxylic acid) and a minor oxidative metabolite (indole-3-carboxaldehyde) were detected in plasma of mice after oral administration of I3C. ICZ was also tentatively identified in the liver of these mice. This study shows for the first time that, after oral administration to mice, I3C, in addition to its acid condensation products, is absorbed from the gut and distributed systemically into a number of well-perfused tissues, thus allowing the possibility for some pharmacological activity of the parent compound in vivo.




This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
G. A. Reed, J. M. Sunega, D. K. Sullivan, J. C. Gray, M. S. Mayo, J. A. Crowell, and A. Hurwitz
Single-Dose Pharmacokinetics and Tolerability of Absorption-Enhanced 3,3'-Diindolylmethane in Healthy Subjects
Cancer Epidemiol. Biomarkers Prev., October 1, 2008; 17(10): 2619 - 2624.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
F.-M. Lin, L.-R. Chen, E.-H. Lin, F.-C. Ke, H.-Y. Chen, M.-J. Tsai, and P.-W. Hsiao
Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells
Carcinogenesis, December 1, 2007; 28(12): 2521 - 2529.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
K. W. Rahman, S. Ali, A. Aboukameel, S. H. Sarkar, Z. Wang, P. A. Philip, W. A. Sakr, and A. Raz
Inactivation of NF-{kappa}B by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells
Mol. Cancer Ther., October 1, 2007; 6(10): 2757 - 2765.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
S. C. Tilton, J. D. Hendricks, G. A. Orner, C. B. Pereira, G. S. Bailey, and D. E. Williams
Gene expression analysis during tumor enhancement by the dietary phytochemical, 3,3'-diindolylmethane, in rainbow trout
Carcinogenesis, July 1, 2007; 28(7): 1589 - 1598.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
G. A. Reed, D. W. Arneson, W. C. Putnam, H. J. Smith, J. C. Gray, D. K. Sullivan, M. S. Mayo, J. A. Crowell, and A. Hurwitz
Single-Dose and Multiple-Dose Administration of Indole-3-Carbinol to Women: Pharmacokinetics Based on 3,3'-Diindolylmethane
Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2477 - 2481.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. L. Petersen, S. Krishnan, and E. D. Hudgens
The Aryl Hydrocarbon Receptor Pathway and Sexual Differentiation of Neuroendocrine Functions
Endocrinology, June 1, 2006; 147(6): s33 - s42.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
S. C. Tilton, S. A. Givan, C. B. Pereira, G. S. Bailey, and D. E. Williams
Toxicogenomic Profiling of the Hepatic Tumor Promoters Indole-3-Carbinol, 17{beta}-Estradiol and {beta}-Naphthoflavone in Rainbow Trout
Toxicol. Sci., March 1, 2006; 90(1): 61 - 72.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. A. Savino III, J. F. Evans, D. Rabinowitz, K. J. Auborn, and T. H. Carter
Multiple, disparate roles for calcium signaling in apoptosis of human prostate and cervical cancer cells exposed to diindolylmethane.
Mol. Cancer Ther., March 1, 2006; 5(3): 556 - 563.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.